Physician profile
Mark A Yoder
NPI 1235597048
$8,957.17
in general payments reported to CMS, 2019-2025
49 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,772 · 2022: $1,502 · 2023: $2,130 · 2024: $2,079 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,669 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,668.76 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,306.70 | 2021-2025 | |
| Novo Nordisk INC | $746.66 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $713.21 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $533.78 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Organogenesis INC. | $409.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.83 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $388.06 | 2021-2025 | Spravato |
| Kerecis Limited | $294.75 | 2021-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Bayer Healthcare Pharmaceuticals INC. | $246.41 | 2022-2023 | |
| Alkermes, INC. | $223.04 | 2024-2025 | Aristada, Vivitrol, Lybalvi |
| Neurocrine Biosciences, INC. | $215.53 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $173.06 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $171.69 | 2022-2025 | Uzedy, Austedo Xr |
| Inspire Medical Systems, INC. | $159.38 | 2024 | Inspire |
| Amgen INC. | $140.76 | 2022-2023 | Evenity, Prolia |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.